Romano Brothers & Co’s Editas Medicine EDIT Stock Holding History

Romano Brothers & Co’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50	Closed	-$444	–	481
2022 Q4	$444	Buy	+50	New	+$549	﹤0.01%	1023

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Romano Brothers & Co's EDIT Position: Q1 2023 in Review

Romano Brothers & Co sold out of Editas Medicine (EDIT) in Q1 2023, closing a stake of 50 shares — an estimated $444 sold.

Romano Brothers & Co first reported a position in EDIT in Q4 2022 and held it in 1 quarter. The position peaked at $444 in Q4 2022. 234 funds tracked by Wall St. Rank hold EDIT as of Q1 2023.

Romano Brothers & Co reported no remaining Editas Medicine position as of Q1 2023 after selling out during the quarter.
Romano Brothers & Co sold 50 Editas Medicine shares in Q1 2023, an estimated $444.
Romano Brothers & Co first reported a position in Editas Medicine in Q4 2022 and held it in 1 quarter.
Romano Brothers & Co's Editas Medicine position peaked at $444 in Q4 2022.
234 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.